Evidence map›Paper›PMID 42420599›Full record

Trial reportBreast cancer research and treatment2026

Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.

Norikazu Masuda, Shigehira Saji, Yasuyuki Kojima, Masahiro Kitada, Hiroshi Tada, Tsutomu Iwasa, Kei Koizumi, Tsuguo Iwatani, Yasuaki Sagara, Takashi Kuwayama and 10 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase III
PubMed Publisher
In one paragraph

Trial report in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03264547 (A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03264547 phase3completednot on this map

A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD)

TypeinterventionalSponsorJapan Breast Cancer Research GroupRan2017 to 2024Enrolled446ConditionsBreast CancerArmsPertuzumab, Trastuzumab, Docetaxel, Paclitaxel, Eribulin
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Norikazu MasudaDepartment of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. nmasuda@alpha.ocn.ne.jp.ORCID http://orcid.org/0000-0002-7302-0278
Shigehira SajiDepartment of Medical Oncology, Fukushima Medical University, Fukushima, Japan.ORCID http://orcid.org/0000-0002-6732-8030
Yasuyuki KojimaInstitute for Clinical Genetics and Genomics / Division of Breast Surgical Oncology, Department of Surgery, Showa Medical University, Tokyo, Japan.ORCID http://orcid.org/0000-0002-9991-0228
Masahiro KitadaDepartment of Breast Disease Center, Asahikawa Medical University Hospital, Hokkaido, Japan.
Hiroshi TadaDepartment of Surgery, Division of Breast and Endocrine Surgery, Tohoku University Graduate School of Medicine, Miyagi, Japan.
Tsutomu IwasaDepartment of Medical Oncology, Kindai University Hospital, Osaka, Japan.
Kei KoizumiDepartment of Surgery 1, Division of Breast Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan.
Tsuguo IwataniDepartment of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kanagawa, Japan.ORCID http://orcid.org/0000-0001-7162-1515
Yasuaki SagaraDepartment of Breast and Thyroid Surgical Oncology, Social Medical Corporation Hakuaikai, Sagara Hospital, Kagoshima, Japan.ORCID http://orcid.org/0000-0001-5705-1739
Takashi KuwayamaDepartment of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0002-6992-6552
Masafumi ShimodaDepartment of Breast and Endocrine Surgery, Hyogo Medical University Hospital, Hyogo, Japan.
Tatsunari SasadaDepartment of Breast and Endocrine Surgery, NHO Higashihiroshima Medical Center, Hiroshima, Japan.
Koichiro TsugawaDepartment of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kanagawa, Japan.
Yoshihiro KawaguchiDepartment of Breast Surgery, Asahi University Hospital, Gifu, Japan.
Akihiko ShimomuraDepartment of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan.
Takuhiro YamaguchiDivision of Biostatistics, Tohoku University Graduate School of Medicine, Miyagi, Japan.ORCID http://orcid.org/0000-0002-7961-9417
Hiroki HasegawaMedical HQs, Eisai Co., Ltd, Tokyo, Japan.
Shun OsakaMedical HQs, Eisai Co., Ltd, Tokyo, Japan.
Satoshi MoritaDepartment of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-4344-3317
Toshinari YamashitaDepartment of Breast Surgery and Oncology, Kanagawa Cancer Center, Kanagawa, Japan.ORCID http://orcid.org/0000-0002-6479-1660

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe performed updated subgroup analyses of the EMERALD study to investigate efficacy, safety, and quality of life (QoL) in patients treated with eribulin (E) vs. either docetaxel (DTX) or paclitaxel (PTX).

methodsPatients with HER2+ locally advanced/metastatic breast cancer (LABC/MBC) were randomized to receive E or taxane (T) (physician's choice of DTX or PTX; declared in advance at registration) in 21-day cycles, each combined with trastuzumab + pertuzumab. Survival outcomes, treatment patterns, antitumor efficacy, safety, and QoL were examined.

resultsThe intention-to-treat (and safety) populations comprised 224 (224) patients who received E, 186 (184) who received DTX, and 36 (34) who received PTX. Baseline characteristics were balanced. Progression-free survival (E vs. DTX: 14.0 vs. 13.1 months; hazard ratio [HR], 0.94 [95% CI, 0.74-1.21]; E vs. PTX: 14.1 vs. 10.8 months; HR, 1.00 [95% CI, 0.58-1.73]) and overall survival (E vs. DTX: not reached [NR] vs. NR; E vs. PTX: 75.5 months vs. NR) were similar among the subgroups. Although the incidences of adverse events (AEs) were generally similar, peripheral sensory neuropathy was more frequent with PTX and less frequent with DTX, compared with E. Neutropenia tended to be more frequent with E. Median time to QoL deterioration was longer with E vs. DTX (7.8 vs. 4.7 months) and E vs. PTX (6.1 vs. 3.9 months).

conclusionsThis trial revealed comparable efficacy of E vs. either DTX or PTX, when combined with dual HER2 blockade as first-line treatment for HER2+ LABC/MBC. AEs were generally similar between the E and T subgroups. QoL was maintained for longer in the E subgroups vs. T subgroups.

trial registrationClinicalTrials.gov (NCT03264547; registered: 28 June 2017); University Hospital Medical Information Network (UMIN000027938; registered: 26 June 2017).

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultAgedAntibodies, Monoclonal, HumanizedDocetaxelFemaleFuransHumansKetonesMiddle AgedNeoplasm MetastasisPaclitaxelPolyether PolyketidesQuality of LifeAntibodies, Monoclonal, HumanizedDocetaxelERBB2 protein, humanErb-b2 Receptor Tyrosine KinaseseribulinFuransKetonesPaclitaxelpertuzumabPolyether PolyketidesTrastuzumabEribulinHER2-positive advanced breast cancerPertuzumab + trastuzumabQuality of lifeTaxane

Identifiers

PMID42420599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.